

EDITORIAL COMMENT

Amyloidosis and Risk of Stroke After Transcatheter Aortic Valve Replacement

It Takes Two to Tango?*

Fabrizio Ricci, MD, PhD, MSc,^{a,b,c} Alberto Cipriani, MD,^d Mohammed Y. Khanji, MBChB, PhD^{e,f,g}



Aortic stenosis (AS) is the most common valvular heart disease in Western countries. Patient symptoms and outcomes related to AS are largely determined by the presence of associated comorbidities, the severity of valve disease and the array of maladaptive changes of the myocardium to chronic pressure overload, such as reactive fibrosis, microvascular ischemia, and cell death with replacement fibrosis, eventually leading to irreversible myocardial dysfunction.¹ Amyloidosis is a protein-folding systemic disease sustained by the extracellular deposition of insoluble abnormal fibrils, with the pathognomonic histological property of green birefringence when viewed under polarized light after staining with Congo red.² Cardiac amyloidosis (CA) is an increasingly recognized cardiomyopathy, mainly derived from transthyretin—either wild-type or hereditary variants—or immunoglobulin light chain amyloid fibrils infiltration of the myocardium.³


AS and CA are common causes of heart failure with preserved ejection fraction in older people and both carry high morbidity and mortality, particularly when left untreated. The increased availability of advanced cardiac imaging tools has led to easier and earlier recognition of CA—mainly wild-type transthyretin—among elderly patients with degenerative AS, with an observed prevalence of coexisting diseases ranging between 6% and 25% in different cohorts.⁴⁻⁶ While dual pathology portends 2-fold heightened mortality compared with each condition alone,^{7,8} observational data have shown that transcatheter aortic valve replacement (TAVR) is still associated with a survival benefit in the presence of dual pathology compared with medical management alone, with similar periprocedural complications rates as for treating lone AS.⁹

In this issue of *JACC: Advances*, Elzeneini et al¹⁰ present an interesting propensity score-weighted retrospective analysis of US hospital discharge data available from the Nationwide Readmission Database that aimed to investigate the impact of dual AS and pre-existing amyloidosis (used as a surrogate for CA) on in-hospital outcomes and 30-day readmission rate of patients undergoing TAVR. Overall, the authors retrieved 273 and 244,694 TAVR-related hospitalizations in AS patients with and without amyloidosis, respectively. Despite similar in-hospital mortality, risk of myocardial infarction, bleeding, acute kidney injury, ventricular arrhythmias, pacemaker implantation, and 30-day readmission rate, the presence of dual pathology was independently associated with a 3-fold higher risk of acute ischemic stroke during hospitalization compared with lone AS, regardless of prevalent atrial fibrillation, prior stroke, and chronic heart failure. The current analysis is inherently limited by selection and case ascertainment biases, observational

*Editorials published in *JACC: Advances* reflect the views of the authors and do not necessarily represent the views of *JACC: Advances* or the American College of Cardiology.

From the ^aDepartment of Neuroscience, Imaging and Clinical Sciences, “G. d’Annunzio” University of Chieti-Pescara, Chieti, Italy; ^bDepartment of Clinical Sciences, Lund University, Malmö, Sweden; ^cFondazione Vil-laserena per la Ricerca, Città Sant’Angelo, Italy; ^dDepartment of Cardio-Thoraco-Vascular Sciences and Public Health, University of Padua, Padua, Italy; ^eNewham University Hospital, Barts Health NHS Trust, London, United Kingdom; ^fBarts Heart Centre, Barts Health NHS Trust, London, United Kingdom; and the ^gNIHR Barts Biomedical Research Centre, William Harvey Research Institute, Queen Mary University of London, London, United Kingdom.

The authors attest they are in compliance with human studies committees and animal welfare regulations of the authors’ institutions and Food and Drug Administration guidelines, including patient consent where appropriate. For more information, visit the [Author Center](#).



retrospective nature of the study, lack of appropriate coding, absence of relevant pieces of information about antithrombotic treatment, procedural details, and imaging data (echocardiography, cardiovascular magnetic resonance, or bone scintigraphy), and very low prevalence of CA in the cohort (0.1% of TAVR recipients), that is suggestive of a global lack of awareness and underdiagnosis. The authors have provided some hypothesis-generating data that points to greater perioperative thromboembolic risk associated with CA. However, further evidence from contemporary and deep phenotyped prospective cohort studies is required to corroborate these findings.^{9,11}

Stroke prevention in patients undergoing TAVR is a complex and unsolved issue, especially while expanding the indication to younger, low-risk populations. Occurrence of cerebrovascular events remains indeed an ominous complication after TAVR, with an incidence of 2% to 3% at 30 days.¹² Risk

factors for stroke after TAVI include patient-related and procedural-related factors that should guide periprocedural strategies¹³ and optimal antithrombotic therapy for stroke prevention.¹⁴ A high frequency of intracardiac thrombosis and high risk for thromboembolic events have been reported in CA patients,^{15,16} with progressive amyloid deposition leading to atrial myopathy,¹⁷ atrial electromechanical dissociation,¹⁸ and acute decompensated AS¹⁹ (Figure 1). This evidence motivated expert recommendations to anticoagulate CA patients with atrial fibrillation independently of the CHA₂DS₂-VASc score, and to perform imaging-guided cardioversion regardless of anticoagulation status.^{20,21} Whether routine anticoagulation should be also considered in systemic amyloidosis, and more specifically CA patients in sinus rhythm, when the atria are enlarged and dysfunctional, and the bleeding risk is low, is yet to be determined. Randomized trials assessing

uninterrupted anticoagulation during TAVR, use of devices for cerebral embolic protection, and specific antithrombotic strategies after TAVR are awaited. In the absence of randomized data on the efficacy and safety of sequential valve- and amyloid-directed therapies in the setting of dual pathology, overall evidence calls for individualized treatment strategies that should come from Heart Team discussion with decisions based on patient life expectancy, frailty, comorbidities, and shared decision-making according to patient values and preferences.

FUNDING SUPPORT AND AUTHOR DISCLOSURES

The authors have reported that they have no relationships relevant to the contents of this paper to disclose.

ADDRESS FOR CORRESPONDENCE: Dr Fabrizio Ricci, Department of Neuroscience, Imaging and Clinical Sciences, “G. d’Annunzio” University of Chieti-Pescara, Via dei Vestini, 33, Chieti 66013, Italy. E-mail: fabrizio.ricci@unich.it. Twitter: [@fabrizioricci](https://twitter.com/fabrizioricci).

REFERENCES

1. Ajmone Marsan N, Delgado V, Shah DJ, et al. Valvular heart disease: shifting the focus to the myocardium. *Eur Heart J*. 2022;44(1):28–40.
2. Wechalekar AD, Gillmore JD, Hawkins PN. Systemic amyloidosis. *Lancet*. 2016;387:2641–2654.
3. Garcia-Pavia P, Rapezzi C, Adler Y, et al. Diagnosis and treatment of cardiac amyloidosis. A position statement of the European Society of Cardiology Working Group on Myocardial and Pericardial Diseases. *Eur J Heart Fail*. 2021;23:512–526.
4. Treibel TA, Fontana M, Gilbertson JA, et al. Occult transthyretin cardiac amyloid in severe calcific aortic stenosis: prevalence and prognosis in patients undergoing surgical aortic valve replacement. *Circ Cardiovasc Imaging*. 2016;9:e005066.
5. Castano A, Narotsky DL, Hamid N, et al. Unveiling transthyretin cardiac amyloidosis and its predictors among elderly patients with severe aortic stenosis undergoing transcatheter aortic valve replacement. *Eur Heart J*. 2017;38:2879–2887.
6. Cavalcante JL, Rijal S, Abdelkarim I, et al. Cardiac amyloidosis is prevalent in older patients with aortic stenosis and carries worse prognosis. *J Cardiovasc Magn Reson*. 2017;19:98.
7. Ricci F, Ceriello L, Khanji MY, et al. Prognostic significance of cardiac amyloidosis in patients with aortic stenosis: a systematic review and meta-analysis. *J Am Coll Cardiol Img*. 2021;14:293–295.
8. Chacko L, Martone R, Bandera F, et al. Echocardiographic phenotype and prognosis in transthyretin cardiac amyloidosis. *Eur Heart J*. 2020;41:1439–1447.
9. Nitsche C, Scully PR, Patel KP, et al. Prevalence and outcomes of concomitant aortic stenosis and cardiac amyloidosis. *J Am Coll Cardiol*. 2021;77:128–139.
10. Elzeneini M, Gupta S, Assaf Y, et al. Outcomes of transcatheter aortic valve replacement in patients with coexisting amyloidosis: mortality, stroke, and readmission. *JACC Adv*. 2023;2(2):100255.
11. Khan MZ, Brailovsky Y, Vishnevsky OA, Baqi A, Patel K, Alvarez RJ. Clinical outcome of TAVR vs. SAVR in patients with cardiac amyloidosis. *Cardiovasc Revasc Med*. 2022;43:20–25.
12. Muralidharan A, Thiagarajan K, Van Ham R, et al. Meta-analysis of perioperative stroke and mortality in transcatheter aortic valve implantation. *Am J Cardiol*. 2016;118:1031–1045.
13. Linder M, Seiffert M. Periprocedural strategies for stroke prevention in patients undergoing transcatheter aortic valve implantation. *Front Cardiovasc Med*. 2022;9:892956.
14. Ten Berg J, Rocca B, Angiolillo DJ, Hayashida K. The search for optimal antithrombotic therapy in transcatheter aortic valve implantation: facts and uncertainties. *Eur Heart J*. 2022;43:4616–4634.
15. Cappelli F, Tini G, Russo D, et al. Arterial thrombo-embolic events in cardiac amyloidosis: a look beyond atrial fibrillation. *Amyloid*. 2021;28:12–18.
16. Russo D, Limite LR, Arcari L, Autore C, Musumeci MB. Predicting the unpredictable: how to score the risk of stroke in cardiac amyloidosis? *J Am Coll Cardiol*. 2019;73:2910–2911.
17. Bisbal F, Baranchuk A, Braunwald E, Bayes de Luna A, Bayes-Genis A. Atrial failure as a clinical entity: JACC review topic of the week. *J Am Coll Cardiol*. 2020;75:222–232.
18. Bandera F, Martone R, Chacko L, et al. Clinical importance of left atrial infiltration in cardiac transthyretin amyloidosis. *J Am Coll Cardiol Img*. 2022;15:17–29.
19. Patel KP, Chahal A, Mullen MJ, et al. Acute decompensated aortic stenosis: state of the art review. *Curr Probl Cardiol*. 2023;48:101422.
20. Donnellan E, Elshazly MB, Vakamudi S, et al. No association between CHADS-VASc score and left atrial appendage thrombus in patients with transthyretin amyloidosis. *J Am Coll Cardiol EP*. 2019;5:1473–1474.
21. Di Lisi D, Di Caccamo L, Damerino G, et al. Effectiveness and safety of oral anticoagulants in cardiac amyloidosis: lights and shadows. *Curr Probl Cardiol*. 2022:101188.

KEY WORDS amyloidosis, aortic stenosis, atrial myopathy, stroke, TAVR